A Multi-Center Phase I Study of Codrituzumab in Pediatric Patients With Relapsed or Refractory Glypican 3 (GPC3) Expressing Extra-cranial Solid Tumors
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Codrituzumab (Primary)
- Indications Hepatoblastoma; Solid tumours
- Focus Adverse reactions
- 27 Jun 2023 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
- 27 Jun 2023 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2025.
- 22 Jun 2021 New trial record